The question is Baldwidx is based on clinical success of Trofinetide and now the very convincing success of 2591, whether BP will wait until then or put in an offer that would be commensurate to success in the remaining 3 trials.
I have no doubt they will be analysing why and how 2591 works with these conditions and working backwards, try and work out why it wouldn’t work in similar conditions, but not just the 4 under trial.
If the science stacks up so to will the numbers
It’s now up to which BP has the bigger cahunas to take the plunge and take ownership of a potentially limitless gold mine
The question is Baldwidx is based on clinical success of...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.70 |
Change
0.520(2.71%) |
Mkt cap ! $2.515B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.84 | $19.28 | $5.675M | 288.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1531 | $19.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.81 | 557 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.70 |
Change
0.520 ( 2.59 %) |
||||
| Open | High | Low | Volume | ||
| $19.50 | $19.84 | $19.28 | 87628 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| NEU (ASX) Chart |